Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Rosiglitazone

2

II.a Pulmonary edema, noncardiogenic (NCPE)

2
Last update : 20/01/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Thiazolidinedione associated volume overload and pulmonary hypertension.
Therapeutic advances in cardiovascular disease 2008 Dec;2;435-8 2008 Dec
Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.
Journal of intensive care medicine 2006;21;47-50 2006
Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
American heart journal 2004 Oct;148;551-8 2004 Oct
Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Mayo Clinic proceedings 2003 Sep;78;1088-91 2003 Sep
Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability.
Diabetologia 2003 Feb;46;288-90 2003 Feb
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Diabetes technology & therapeutics 2002;4;505-14 2002

Powered by

  • ^
  • Contact
  • Cookies
  • About